Detalhe da pesquisa
1.
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Lancet Oncol
; 25(4): 463-473, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38467131
2.
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
Leukemia
; 37(10): 2036-2049, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37528310